SOURCE: BIOLASE Technology, Inc.

May 15, 2007 06:00 ET

BIOLASE Announces Launch of Its ezlase™ "810 Model" Soft Tissue Diode Laser

IRVINE, CA -- (MARKET WIRE) -- May 15, 2007 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that it will be launching its new "810 Model" of the ezlase™ soft tissue diode dental laser this week.

"The addition of this new 810nm wavelength model of the ezlase to our product portfolio will provide the customer with more options when choosing the ideal diode laser for his or her particular practice," commented Jeffrey W. Jones, President and CEO. "We believe this will accelerate the excellent start we have already experienced in selling the recently launched ezlase 940."

Both the 810 and 940nm versions of the ezlase diode laser utilize the Company's innovative ComfortPulse™ pulse technology, which in clinical use by experienced diode laser users has demonstrated greater patient comfort. Both versions also feature easy-to-use procedure-based presets accessed via an iPod®-like navigation wheel or color touch screen, ultralight fiber and handpiece, innovative low-cost disposable tips, infinite pulse combinations which deliver laser energy by dose, and wireless foot pedal.

iPod is a registered trademark of Apple Inc.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies for improved applications and procedures in dentistry and medicine. The Company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase® system, is one of the best selling dental laser systems. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The Company also offers the LaserSmile™ system, which uses a laser to perform soft tissue and cosmetic procedures, including teeth whitening. The Company is also developing a laser for use in the field of ophthalmology.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jeffrey W. Jones
    President & CEO
    Richard L. Harrison
    Executive Vice President and CFO
    BIOLASE Technology, Inc.
    +1-949-361-1200

    Jill Bertotti
    Allen & Caron
    +1-949-474-4300